Terms: = Kidney tumors AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
57 results:
1. Sarcoid-like reaction and hypothyroidism induced by pd-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review.
Shrateh ON; Abugharbieh Y; Asbeh YA; Hour H; Awad I; Bannoura S
BMC Pulm Med; 2024 Mar; 24(1):123. PubMed ID: 38459507
[TBL] [Abstract] [Full Text] [Related]
2. Prognosis and Clinicopathological Characters of Adult TFEB-Altered Renal Cell Carcinoma: A Single Center Experience of 18 Cases.
Wu J; Cao CZ; Cui HL; Du G; Shi HZ; Liang J; Guo L; Wang YC; Zhang J; Zhou AP; Li CL; Zheng S; Shou JZ
Clin Genitourin Cancer; 2024 Apr; 22(2):261-268.e3. PubMed ID: 38104031
[TBL] [Abstract] [Full Text] [Related]
3. Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.
Weinberg OK; Pinkus GC; Ramos-Gonzalez GJ; Agur T; Rodig NM
Clin Transplant; 2023 Dec; 37(12):e15134. PubMed ID: 37772613
[TBL] [Abstract] [Full Text] [Related]
4. Acute kidney injury in patients with cancer receiving anti-pd-1/PD-L1 antibodies: incidence, risk factors, and prognosis.
Lou Q; Gong J; Ye B; Yu R; Bu S; Li Y; Zhu B; Shao L
Ren Fail; 2023 Dec; 45(1):2238823. PubMed ID: 37491871
[TBL] [Abstract] [Full Text] [Related]
5. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
[TBL] [Abstract] [Full Text] [Related]
6. Renal Sarcoidosis-like Reaction Induced by pd-1 Inhibitor Treatment in Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Park SD; Kim MS; Han MH; Kim YJ; Jung HY; Choi JY; Cho JH; Park SH; Kim CD; Kim YL; Lim JH
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241223
[TBL] [Abstract] [Full Text] [Related]
7. Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report.
Yang Z; Xu H; Gou S; Wu H; Hu Z
BMC Nephrol; 2023 May; 24(1):145. PubMed ID: 37226096
[TBL] [Abstract] [Full Text] [Related]
8. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Rouprêt M; Seisen T; Birtle AJ; Capoun O; Compérat EM; Dominguez-Escrig JL; Gürses Andersson I; Liedberg F; Mariappan P; Hugh Mostafid A; Pradere B; van Rhijn BWG; Shariat SF; Rai BP; Soria F; Soukup V; Wood RG; Xylinas EN; Masson-Lecomte A; Gontero P
Eur Urol; 2023 Jul; 84(1):49-64. PubMed ID: 36967359
[TBL] [Abstract] [Full Text] [Related]
9. Construction of a prognostic prediction model for renal clear cell carcinoma combining clinical traits.
Weng Y; Ning P
Sci Rep; 2023 Feb; 13(1):3358. PubMed ID: 36849551
[TBL] [Abstract] [Full Text] [Related]
10. A lung squamous cell carcinoma-associated membranous nephropathy patient free of tumor and membranous nephropathy after the treatment of surgery and radiochemotherapy following pembrolizumab: A rare case report.
Chen F; Du H; Fang S
Medicine (Baltimore); 2023 Jan; 102(3):e32508. PubMed ID: 36701715
[TBL] [Abstract] [Full Text] [Related]
11. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
Khazaeli M; Grover R; Pei S
J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
[TBL] [Abstract] [Full Text] [Related]
12. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.
Han X; Meng M; Zhang T; Wang J; Huang G; Ni Y; Li W; Dai J; Yang X; Ye X
J Cancer Res Ther; 2022 Sep; 18(5):1440-1443. PubMed ID: 36204895
[TBL] [Abstract] [Full Text] [Related]
13. Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021.
Liu K; Zhao S; Li J; Zheng Y; Wu H; Kong J; Shen Z
Front Immunol; 2022; 13():969217. PubMed ID: 35967367
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma.
Zhou L; Liu Y; Mo J; Cui C; Chi Z; Si L; Kong Y; Yan X; Li S; Wu X; Li J; Xu H; Cao D; Guo J; Sheng X
Urol Oncol; 2022 Aug; 40(8):385.e1-385.e8. PubMed ID: 35773144
[TBL] [Abstract] [Full Text] [Related]
16. Extranodal NK/T-cell lymphoma: a case report of renal insufficiency during pd1 inhibitor treatment.
Hu HY; Xie XX; Tan ST; Fan X; He J
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3827-3831. PubMed ID: 35731051
[TBL] [Abstract] [Full Text] [Related]
17. Clear Cell Renal Cell Carcinoma with Immunotherapy Effect Mimicking Xanthogranulomatous Pyelonephritis.
Wang Y; Ganesan S; Williamson SR; Rayes-Danan R
Int J Surg Pathol; 2023 May; 31(3):316-320. PubMed ID: 35570589
[TBL] [Abstract] [Full Text] [Related]
18. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract] [Full Text] [Related]
19. Toxicity profile of treatment with pd-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study.
Duarte HS; Veiga CRP; Veiga CP; Wainstein AJA; Drummond-Lage AP
Int Immunopharmacol; 2022 Jul; 108():108727. PubMed ID: 35397393
[TBL] [Abstract] [Full Text] [Related]
20. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract] [Full Text] [Related]
[Next]
